A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs CHR 5154 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Sep 2017 Planned End Date changed from 4 May 2018 to 1 Feb 2019.
- 25 Sep 2017 Planned primary completion date changed from 1 May 2018 to 1 Feb 2019.
- 10 Jun 2017 Biomarkers information updated